AI In Remote Patient Monitoring - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI in remote patient monitoring market is expected to grow from USD 2.15 billion in 2025 to USD 2.44 billion in 2026 and is forecasted to reach USD 5.20 billion by 2031 at 16384% CAGR over 2026-2031. This report is Segmented by Component (Software Platform, Services), Deployment Mode (Cloud-Based, On-Premise), Application (Cardiovascular Monitoring, Diabetes and Metabolic Disorders, and Others), End-User (Hospitals and Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI In Remote Patient Monitoring Market Trends and Insights

Ubiquitous Chronic-Disease Burden and Telehealth Reimbursement Mandates

The AI in remote patient monitoring market is seeing durable demand because chronic disease management requires contact far more often than periodic office visits can provide. Noncommunicable diseases now account for 74% of global deaths, with cardiovascular disease, diabetes, and chronic respiratory illness carrying a major share of that burden. That clinical need is turning into spend because the CMS ACCESS model links recurring chronic care payments to health outcomes rather than to device activity alone. Medicare also continues to scale its use of remote monitoring, with payments above USD 536 million in 2024 and enrollment nearing 1 million beneficiaries. Published program evidence is helping health systems justify larger budgets, with a Mayo Clinic Proceedings study highlighted in late 2025 showing lower total cost of care and lower inpatient spending for patients in a structured RPM program. As that financial case becomes clearer, the AI in remote patient monitoring market is moving further into mainstream care pathways.

Advancements in AI-Enabled Edge Processing and Wearable Efficiency

The AI in remote patient monitoring market is gaining from better on-device inference, because more signal processing can now happen at the point of capture instead of being pushed to the cloud first. That shift helps lower bandwidth demand, improves device efficiency, and makes continuous monitoring more practical for longer wear periods. It also changes where differentiation sits, since better chip performance alone does not remove the value of proprietary algorithms and labeled training data. In the AI in remote patient monitoring market, vendors with strong biosignal libraries still have an advantage when they train deterioration detection, rhythm analysis, or predictive risk models. iRhythm has pointed to more than 3 billion hours of curated ECG data and continued algorithm development, which shows how data depth can remain a moat even as hardware improves.The result is that better wearables support growth, but the strongest pricing power is still likely to sit with platforms that combine efficient hardware with clinically validated AI.

Algorithmic Bias and Clinical-Validation Gaps Slowing FDA/EMA Approvals

The AI in remote patient monitoring market still faces a meaningful restraint from uneven validation quality across AI-enabled medical devices. A 2025 review discussed by the American Hospital Association found 60 AI-enabled devices linked to 182 recall events, with 43% of those recalls occurring within 1 year of initial clearance. That pattern matters because many AI devices still reach market with limited prospective real-world testing. A peer-reviewed 2025 study found that machine learning models could infer race or ethnicity from vital-sign values alone, which points to fairness risks that standard performance metrics may miss. Another 2025 study in npj Cardiovascular Health showed that deep learning models trained on ECG signals could surface different outcomes across racial groups even in the absence of genetic explanations. For the AI in remote patient monitoring market, this means validation now has to cover accuracy, safety, and demographic equity at the same time, which raises the cost and complexity of expansion across multiple conditions.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Hospital-at-Home and Decentralized Care Delivery Models
• Shift Toward Value-Based Care and Population Health Management Programs
• Cyber-Security Liabilities for Multi-Tenant Cloud RPM Platforms

Segment Analysis

Software platforms held 70.24% of the AI in remote patient monitoring market share in 2025, which shows how much value sits in analytics, alerting, and model orchestration rather than in sensor hardware alone. The AI in remote patient monitoring market has favored software because recurring licensing revenue is easier to scale when the core intelligence sits in the platform layer. That advantage is strongest among vendors that have built proprietary models on large labeled biosignal datasets. Their differentiation is harder to copy quickly because clinical training data take time, workflow access, and long validation cycles to assemble. Even so, the software lead does not mean the rest of the value chain is standing still.

Services are projected to grow at a 17.47% CAGR from 2026 to 2031, which places them slightly ahead of the overall AI in remote patient monitoring market. Health systems increasingly prefer managed RPM programs where the vendor supports workflow setup, patient engagement, reporting, and operating execution. That shift reduces the buyer’s internal burden and makes the purchase decision less about a software seat and more about ongoing performance delivery. The AI in remote patient monitoring industry is therefore moving toward a two-layer model where the platform remains important, but services increasingly determine retention and account growth.

Cloud-based deployment accounted for 55.76% of the AI in remote patient monitoring market size in 2025, and it is also projected to grow at the fastest 18.37% CAGR through 2031. This is the only major segmentation line in the AI in remote patient monitoring market where the largest segment is also the fastest-growing one. The explanation is straightforward because AI retraining on streaming biosignal data requires elastic compute and storage that are hard to match economically with local installations. Cloud delivery also makes updates, analytics rollouts, and multi-site scaling easier for provider organizations. Even so, strong growth in cloud does not mean on-premise deployment loses all relevance.

On-premise deployment continues to hold a structural niche in the AI in remote patient monitoring market where data residency, sovereignty, and compliance requirements remain strict. A 2025 JMIR AI study also showed a federated deep learning setup that linked 12 hospitals across 8 nations and 4 continents without moving raw patient data across borders. That model shows how hybrid architectures can preserve local data control while still supporting broader algorithm development. Vendors that combine cloud-scale training with local inference are likely to be better positioned in regulated parts of the AI in remote patient monitoring market.

Complete Report Scope:

• By Component
  • Software Platform
  • Services
• By Deployment Mode
  • Cloud-Based
  • On-Premise
• By Application
  • Cardiovascular Monitoring
  • Diabetes and Metabolic Disorders
  • Respiratory Monitoring
  • Oncology and Specialty Care
  • Post-Acute and Chronic Care Management
  • Sleep and Mental Health Monitoring
  • Other Applications
• By End-User
  • Hospitals and Clinics
  • Home-Care Settings
  • Ambulatory Surgical centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 54.37% of the AI in remote patient monitoring market size in 2025, which keeps it as the largest regional contributor. The AI in remote patient monitoring market is strongest in North America because the United States already has a mature reimbursement path and a provider base that has expanded RPM programs over several years. Medicare payments for remote monitoring services exceeded USD 536 million in 2024, and nearly 1 million enrollees received RPM services during that year. The 2026 extension of Hospital-at-Home through 2030 adds further structural support for AI-enabled home monitoring in the region.

Asia-Pacific is projected to grow at a 19.62% CAGR from 2026 to 2031, making it the fastest-growing region in the AI in remote patient monitoring market. Growth in the AI in remote patient monitoring market across Asia-Pacific is being driven by demographic scale, rising chronic disease pressure, and improving digital health infrastructure. China remains important because its aging population and chronic care burden create strong demand for scalable monitoring, while tighter quality expectations are likely to favor clinically reliable devices over consumer-grade offerings. Japan, Australia, and South Korea are also supporting uptake through digital health programs, while India remains a longer-horizon opportunity as telehealth regulation and care infrastructure continue to mature.

Europe remains a large part of the AI in remote patient monitoring market, but it is structurally more complex because healthcare delivery and payment rules vary by country. Germany’s digitalization push, including mandatory electronic patient records and an official strategy to integrate digital innovation more deeply into care, is creating a clearer direction for RPM adoption. The United Kingdom, France, Italy, and Spain are building national digital health systems that create procurement openings but also raise interoperability expectations. In the AI in remote patient monitoring market, the Middle East and Africa are growing from a smaller base, led by GCC investment in digital health, while South America remains centered on private network adoption in Brazil and Argentina.

List of Companies Covered in this Report:

• Abbott Laboratories
• AliveCor
• AMC Health
• Apple
• Biofourmis Inc.
• Current Health Ltd.
• Dexcom
• Google LLC
• iRhythm Technologies
• Koninklijke Philips
• Masimo
• Medtronic
• Nihon Kohden
• Omada Health
• Preventice Solutions
• Qardio Inc.
• Resmed
• Teladoc Health
• VitalConnect Inc.
• Withings S.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support